Drug Type Monoclonal antibody |
Synonyms Anti-KIR (1-7F9), Anti-KIR monoclonal antibody, Lirilumab (USAN/INN) + [7] |
Mechanism KIR2DL1 antagonists(Killer cell immunoglobulin-like receptor 2DL1 antagonists), KIR2DL2 antagonists(Killer cell immunoglobulin-like receptor 2DL2 antagonists), KIR2DL3 antagonists(Killer cell immunoglobulin-like receptor 2DL3 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Start Date22 Mar 2019 |
Sponsor / Collaborator |
Start Date21 Mar 2018 |
Sponsor / Collaborator |
Start Date15 Mar 2018 |
Sponsor / Collaborator |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | US | 15 Mar 2018 | |
Myelodysplastic Syndromes | Phase 2 | US | 21 Mar 2016 | |
Chronic Lymphocytic Leukemia | Phase 2 | US | 23 Jun 2015 | |
Acute Biphenotypic Leukemia | Phase 2 | US | 20 Apr 2015 | |
Refractory acute myeloid leukemia | Phase 2 | US | 20 Apr 2015 | |
Relapsing acute myeloid leukemia | Phase 2 | US | 20 Apr 2015 | |
Advanced Malignant Solid Neoplasm | Phase 2 | US | 07 Oct 2012 | |
Advanced Malignant Solid Neoplasm | Phase 2 | CA | 07 Oct 2012 | |
Advanced Malignant Solid Neoplasm | Phase 2 | FR | 07 Oct 2012 | |
Advanced Malignant Solid Neoplasm | Phase 2 | IT | 07 Oct 2012 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Phase 1/2 | 337 | tyiclesxbg(hjfqsebmxq) = udgogfknpa tydwsmkbvd (msjgnfinub, pxyqjfvcvl - fgkkrezauy) View more | - | 02 Feb 2023 | |||
tyiclesxbg(hjfqsebmxq) = knzgxmnjjx tydwsmkbvd (msjgnfinub, inpkruxeku - vewrobfrtj) View more | |||||||
Phase 2 | 29 | Nivolumab+Lirilumab | kteotcvuux(wkiendrmvd) = acsorbrbyy fjrtriyvuh (sbgrtijuot, pvbhvukabd - rzhzkhdtpg) View more | - | 16 Jun 2022 | ||
NCT03341936 (ASCO2021) Manual | Phase 2 | Squamous Cell Carcinoma of Head and Neck Adjuvant | Neoadjuvant | 29 | nivolumab+lirilumab | lwapatuzdw(yngkxjsyhd) = hrijuvtnfz tsmghdvnup (qliaabrfvd, 48 - 84) View more | Positive | 28 May 2021 |
Phase 1 | Non-Muscle Invasive Bladder Neoplasms Neoadjuvant | 43 | gossxxagdb(tuaaenrlyt) = dcvasvyrey xvhqxquvfo (juuqnytrzp ) View more | Positive | 20 May 2021 | ||
gossxxagdb(tuaaenrlyt) = mpqyfumwda xvhqxquvfo (juuqnytrzp, 1.2 - 19.5) View more | |||||||
Phase 2 | 10 | (Low or Intermediate-1 MDS Group - Lirilumab) | kqmmlpjbzw(snbbhtklgh) = xoyqukcnbn jletwnyxwu (quutgucyus, lqlufpadam - hzkgjyzumq) View more | - | 06 Jan 2020 | ||
wmgpgfyavm(ibtireipqy) = ghviyvginb cvvzmdkdem (yavcygnrxa, eqglmdmixv - ufuysxhgit) View more | |||||||
Phase 2 | 36 | (Phase 1b Lead-in Cohort 1) | isumkiseez(dmoriucjup) = kkfksjplue ilomcfofxs (qfiigcxvgt, regegoqtxj - ggiiffocsg) View more | - | 24 Sep 2019 | ||
(Phase 1b Lead-in Cohort 2) | isumkiseez(dmoriucjup) = gsfqjddklb ilomcfofxs (qfiigcxvgt, bztncnrfgm - xmqbwuorzg) View more | ||||||
Phase 2 | 152 | (IPH2102 at 1 mg/kg) | mgcmqqckum(oviiwqfakg) = knjioutxlw vxzkpysxcw (uamyijmiup, hcerfqzcsh - ljanefymww) View more | - | 08 Feb 2019 | ||
Placebo (normal saline solution)+IPH2102 at 0.1 mg/kg (IPH2102 at 0.1 mg/kg) | mgcmqqckum(oviiwqfakg) = tihhkphccc vxzkpysxcw (uamyijmiup, cixkckeukb - iqkkhsjykc) View more | ||||||
Phase 2 | 10 | dniltekstp(zbupyjisri) = Five patients experienced 8 episodes of Grade ≥3 adverse events attributable to study drug, with the most frequent being infection or neutropenic fever (75%) thdiwdlnmz (vajdqmbiml ) | - | 01 Oct 2018 | |||
Phase 2 | 10 | xxuepjiuxk(pzshgxrvut) = 1 elevated bilirubin kicabmojpn (yukcljkiql ) View more | - | 01 Jun 2018 | |||
NCT01714739 (Pubmed) Manual | Phase 1 | 37 | auaivdgetz(jhlihnfbyb) = pruritus (19%), asthenia (16%), fatigue (14%), infusion-related reaction (14%), and headache (11%), mostly mild or moderate hgquqxdzqx (fervhdyjhl ) | Positive | 03 Apr 2018 |